iData Insights

Ischemic Stroke - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Dec 01, 2015 16:27 IST

Ischemic Stroke - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemic Stroke - Pipeline Review, H2 2015, provides an overview of the Ischemic Strokes therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC @

To Get Sample Copy of Report visit @

Table of Contents

Table of Contents

2 List of Tables

6 List of Figures

8 Introduction

9 Global Markets Direct Report Coverage

9 Ischemic Stroke Overview

10 Therapeutics Development

11 Pipeline Products for Ischemic Stroke - Overview

11 Pipeline Products for Ischemic Stroke - Comparative Analysis 12 Ischemic Stroke - Therapeutics under Development by Companies

13 Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes 18 Ischemic Stroke - Pipeline Products Glance

19 Late Stage Products

19 Clinical Stage Products

20 Early Stage Products

21 Ischemic Stroke - Products under Development by Companies

22 Ischemic Stroke - Products under Investigation by Universities/Institutes

27 Ischemic Stroke - Companies Involved in Therapeutics Development

28 AB Science SA

28 Acticor Biotech

29 advanceCor GmbH

30 Angion Biomedica Corp.

31 AstraZeneca Plc

32 Athersys, Inc.

33 biOasis Technologies Inc.

34 Biogen, Inc.

35 BioTime, Inc.

36 D-Pharm Ltd. 37 Daiichi Sankyo Company, Limited 38 DiaMedica Inc.

39 Digna Biotech, S.L. 40 Genervon Biopharmaceuticals, LLC

41 Glialogix, Inc.

42 Glucox Biotech AB

43 Grifols, S.A.

44 Huons Co., Ltd.

45 International Stem Cell Corporation

46 JN-International Medical Corporation 47 Laboratoires Pierre Fabre SA

48 Lumosa Therapeutics Co., Ltd.

49 MediaPharma s.r.l.

50 Mitsubishi Tanabe Pharma Corporation

51 Neuralstem, Inc.

52 Neurotec Pharma SL

53 NeuroVive Pharmaceutical AB

54 NoNO, Inc.

55 Panacea Pharmaceuticals, Inc.

56 Pharmicell Co., Ltd.

57 PhytoHealth Corporation

58 Remedy Pharmaceuticals, Inc.

59 ReNeuron Group Plc

60 SanBio, Inc.

61 Saneron CCEL Therapeutics, Inc.

62 Simcere Pharmaceutical Group

63 Stemedica Cell Technologies, Inc.

64 SynZyme Technologies, LLC

65 The International Biotechnology Center (IBC) Generium

66 TikoMed AB

67 vasopharm GmbH 68 Vicore Pharma AB

69 Virogenomics, Inc.

70 Ischemic Stroke - Therapeutics Assessment

71 Assessment by Monotherapy Products

71 Assessment by Target

72 Assessment by Mechanism of Action

76 Assessment by Route of Administration

79 Assessment by Molecule Type

81 Drug Profiles

83 3K3A-APC - Drug Profile

83 ACT-017 - Drug Profile

85 alteplase biosimilar - Drug Profile

86 BB-3 - Drug Profile

87 BSc-2118 - Drug Profile

90 C-21 - Drug Profile

91 Cerecellgram-Stroke - Drug Profile

93 CNB-001 - Drug Profile

94 DB-017 - Drug Profile

96 DM-199 - Drug Profile

97 Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile

98 DS-1040 - Drug Profile

99 GLX-1112 - Drug Profile

100 glyburide - Drug Profile

101 GM-602 - Drug Profile

103 GXNPC-1 - Drug Profile

104 HBN-1 - Drug Profile

105 HU-010 - Drug Profile

106 Human Plasmin - Drug Profile

107 Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile

109 ISC-hpNSC - Drug Profile

112 levomilnacipran hydrochloride ER - Drug Profile

114 LT-3001 - Drug Profile

116 Lysimab - Drug Profile

117 masitinib - Drug Profile

118 Memantine Nitrone - Drug Profile

123 Mesenchymal Stem Cells - Drug Profile 124 MP-

124 - Drug Profile 126 MPHE-001A - Drug Profile

127 MTfp-siRNA - Drug Profile 128 MultiStem - Drug Profile

129 NA-1 - Drug Profile

133 natalizumab - Drug Profile

135 NSI-566 - Drug Profile

137 NTKC-005 - Drug Profile

139 NVP-014 - Drug Profile

140 NVX-208 - Drug Profile

141 PAN-811 - Drug Profile

142 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile

144 PHN-014 - Drug Profile

146 Pinocembrin - Drug Profile

147 Polyglactin

370 for Ischemic Stroke - Drug Profile

148 PR-15 - Drug Profile

149 prasugrel hydrochloride - Drug Profile

151 Protein for Ischemic Stroke - Drug Profile

154 Protein for Ischemic Stroke - Drug Profile

155 Protein for Ischemic Stroke - Drug Profile

156 Recombinant Peptide for Ischemic Stroke - Drug Profile

157 Recombinant Plasmin - Drug Profile

159 Recombinant Protein for Ischemic Cerebral Stroke and Myocardial Ischemia - Drug Profile

160 Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile

161 ReN-001 - Drug Profile

162 RTL-551 - Drug Profile

164 SB-623 - Drug Profile

166 SIM-071201 - Drug Profile

168 Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile

169 Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile

170 Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile

171 Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile

172 Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile

173 Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile

174 Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile

175 Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile

176 SMTP-7 - Drug Profile 177 StromAb - Drug Profile

178 T-33 - Drug Profile

180 TF-0023 - Drug Profile

181 THR-18 - Drug Profile

182 ticagrelor - Drug Profile

183 TM-700 - Drug Profile

187 TPAi-14 - Drug Profile

188 TPAi-23 - Drug Profile

189 TS-01 - Drug Profile

190 TXA-127 - Drug Profile

191 TXA-302 - Drug Profile

193 UCCB-01144 - Drug Profile

195 Vaccine to Target NMDAR1 for Ischemic Stroke - Drug Profile

196 VACNO - Drug Profile

197 VAS-2870 - Drug Profile

198 Ischemic Stroke - Recent Pipeline Updates

199 Ischemic Stroke - Dormant Projects

255 Ischemic Stroke - Discontinued Products

260 Ischemic Stroke - Product Development Milestones

263 Featured News & Press Releases

263 Appendix

270 Methodology

270 Coverage

270 Secondary Research

270 Primary Research

270 Expert Panel Validation

270 Contact Us

270 Disclaimer

Read More @

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

Contact Us:
iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.